Stuart P McCluskey1,2, Anna Haslop1, Christopher Coello2, Roger N Gunn2,3, Edward W Tate1, Richard Southworth4, Christophe Plisson2, Nicholas J Long5, Lisa A Wells2. 1. Department of Chemistry, Imperial College London, London, United Kingdom. 2. Invicro LLC, London, United Kingdom. 3. Division of Brain Sciences, Imperial College London, Imperial College Centre for Drug Discovery Science, London, United Kingdom; and. 4. Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom. 5. Department of Chemistry, Imperial College London, London, United Kingdom n.long@imperial.ac.uk.
Abstract
Many chemotherapy agents are toxic to the heart, such that increasing numbers of cancer survivors are now living with the potentially lethal cardiovascular consequences of their treatment. Earlier and more sensitive detection of chemotherapy-induced cardiotoxicity may allow improved treatment strategies and increase long-term survival. Lipophilic cation PET tracers may be suitable for early detection of cardiotoxicity. This study aimed to evaluate an 18F-labeled lipophilic phosphonium cation, [1-(2-18F-fluoroethyl),1H[1,2,3]triazole-4-ethylene]triphenylphosphonium bromide (18F-MitoPhos), as a cardiac imaging agent, comparing it with leading PET and SPECT lipophilic cationic tracers before further assessing its potential for imaging cardiotoxicity in an acute doxorubicin model. Methods: Cardiac uptake and response to decreased mitochondrial membrane potential of 18F-MitoPhos and 99mTc-sestamibi were tested in isolated perfused rat hearts. Baseline pharmacokinetic profiles of 18F-MitoPhos and 18F-fluorobenzyltriphenylphosphonium and their response to acute doxorubicin-induced cardiotoxicity were assessed in rats in vivo (10, 15, or 20 mg of doxorubicin per kilogram, intravenously, 48 h beforehand). Results: Cardiac retention of 18F-MitoPhos was more than double that of 99mTc-sestamibi in isolated perfused rat hearts. A favorable biodistribution of 18F-MitoPhos in vivo was observed, with heart-to-tissue ratios of 304 ± 186, 11.2 ± 1.2, and 3.8 ± 0.6 for plasma, liver, and lung, respectively (60 min). A significant dose-dependent loss of cardiac retention of 18F-MitoPhos was observed on doxorubicin treatment, with average cardiac SUV from 30 to 60 min (mean ± SD) decreasing from 3.5 ± 0.5 (control) to 1.8 ± 0.1 (doxorubicin, 20 mg/kg). Other assessed biomarkers showed no alterations. Conclusion: 18F-MitoPhos showed pharmacokinetic parameters suitable for cardiac imaging. A significant dose response of cardiac uptake to doxorubicin treatment was observed before detectable biomarker alterations. 18F-MitoPhos is therefore a promising tracer for imaging chemotherapy-induced cardiotoxicity. To our knowledge, this is the first demonstration of radiolabeled lipophilic cations being used for the PET imaging of chemotherapy-induced cardiotoxicity and indicates the potential application of these compounds in this area.
Many chemotherapy agents are toxic to the heart, such that increasing numbers of cancer survivors are now living with the potentially lethal cardiovascular consequences of their treatment. Earlier and more sensitive detection of chemotherapy-induced cardiotoxicity may allow improved treatment strategies and increase long-term survival. Lipophilic cation PET tracers may be suitable for early detection of cardiotoxicity. This study aimed to evaluate an 18F-labeled lipophilic phosphonium cation, [1-(2-18F-fluoroethyl),1H[1,2,3]triazole-4-ethylene]triphenylphosphonium bromide (18F-MitoPhos), as a cardiac imaging agent, comparing it with leading PET and SPECT lipophilic cationic tracers before further assessing its potential for imaging cardiotoxicity in an acute doxorubicin model. Methods: Cardiac uptake and response to decreased mitochondrial membrane potential of 18F-MitoPhos and 99mTc-sestamibi were tested in isolated perfused rat hearts. Baseline pharmacokinetic profiles of 18F-MitoPhos and 18F-fluorobenzyltriphenylphosphonium and their response to acute doxorubicin-induced cardiotoxicity were assessed in rats in vivo (10, 15, or 20 mg of doxorubicin per kilogram, intravenously, 48 h beforehand). Results:Cardiac retention of 18F-MitoPhos was more than double that of 99mTc-sestamibi in isolated perfused rat hearts. A favorable biodistribution of 18F-MitoPhos in vivo was observed, with heart-to-tissue ratios of 304 ± 186, 11.2 ± 1.2, and 3.8 ± 0.6 for plasma, liver, and lung, respectively (60 min). A significant dose-dependent loss of cardiac retention of 18F-MitoPhos was observed on doxorubicin treatment, with average cardiac SUV from 30 to 60 min (mean ± SD) decreasing from 3.5 ± 0.5 (control) to 1.8 ± 0.1 (doxorubicin, 20 mg/kg). Other assessed biomarkers showed no alterations. Conclusion:18F-MitoPhos showed pharmacokinetic parameters suitable for cardiac imaging. A significant dose response of cardiac uptake to doxorubicin treatment was observed before detectable biomarker alterations. 18F-MitoPhos is therefore a promising tracer for imaging chemotherapy-induced cardiotoxicity. To our knowledge, this is the first demonstration of radiolabeled lipophilic cations being used for the PET imaging of chemotherapy-induced cardiotoxicity and indicates the potential application of these compounds in this area.
Authors: Roelof J Bennink; Maurice J van den Hoff; Formijn J van Hemert; Kora M de Bruin; Astrid L Spijkerboer; Jean-Luc Vanderheyden; Neil Steinmetz; Berthe L van Eck-Smit Journal: J Nucl Med Date: 2004-05 Impact factor: 10.057
Authors: Erika Mariotti; Mattia Veronese; Joel T Dunn; Rodolfo A Medina; Philip J Blower; Richard Southworth; Thomas R Eykyn Journal: EJNMMI Res Date: 2013-11-14 Impact factor: 3.138
Authors: Nathaniel M Alpert; Matthieu Pelletier-Galarneau; Sally Ji Who Kim; Yoann Petibon; Tao Sun; Karla M Ramos-Torres; Marc D Normandin; Georges El Fakhri Journal: Front Physiol Date: 2020-05-15 Impact factor: 4.566
Authors: Felicitas J Detmer; Nathaniel M Alpert; Sung-Hyun Moon; Maeva Dhaynaut; J Luis Guerrero; Nicolas J Guehl; Fangxu Xing; Pedro Brugarolas; Timothy M Shoup; Marc D Normandin; Matthieu Pelletier-Galarneau; Georges El Fakhri; Yoann Petibon Journal: Sci Rep Date: 2022-04-12 Impact factor: 4.379
Authors: Matthieu Pelletier-Galarneau; Yoann Petibon; Chao Ma; Paul Han; Sally Ji Who Kim; Felicitas J Detmer; Daniel Yokell; Nicolas Guehl; Marc Normandin; Georges El Fakhri; Nathaniel M Alpert Journal: Eur J Nucl Med Mol Imaging Date: 2020-07-27 Impact factor: 9.236